4.6 Review

The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?

Journal

CANCERS
Volume 14, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14122887

Keywords

prostate cancer; extracellular matrix stiffening; androgen receptor; androgen deprivation therapy; mechanosensing; metastasis

Categories

Funding

  1. Government of Canada's New Frontiers in Research Fund (NFRF) [NFRFE-2018-00191]
  2. Canadian Institutes of Health Research [PJT-180368]
  3. 100 Days Across Canada Bursary Award

Ask authors/readers for more resources

Prostate cancer affects a large number of men worldwide. Understanding the mechanisms of disease progression and therapy resistance is crucial for developing effective treatments. Alterations in the extracellular matrix, particularly stiffening, play a role in prostate cancer progression. This review examines the association between extracellular matrix stiffening and disease progression and castration resistance in prostate cancer.
Simple Summary Prostate cancer is a malignancy that affects a high number of men all over the world. When indolent, prostate cancer can remain silent for years without needing medical intervention. However, aggressive prostate cancer can grow fast, resist treatment, and cause morbidity and ultimately death. Uncovering mechanisms of prostate cancer disease progression and therapy resistance is important to develop new treatments that help patients live longer and healthier. The extracellular matrix, which provides physical support for tissues and organs, is emerging as an important mediator of disease, especially in cancer. In this review, we examine how extracellular matrix alteration, primarily through stiffening, can affect prostate cancer disease course. We look at mechanisms that involve the androgen receptor, which lies at the center of the disease transcriptional landscape, as well as alternative pathways that are androgen receptor-independent. Despite advancements made in diagnosis and treatment, prostate cancer remains the second most diagnosed cancer among men worldwide in 2020, and the first in North America and Europe. Patients with localized disease usually respond well to first-line treatments, however, up to 30% develop castration-resistant prostate cancer (CRPC), which is often metastatic, making this stage of the disease incurable and ultimately fatal. Over the last years, interest has grown into the extracellular matrix (ECM) stiffening as an important mediator of diseases, including cancers. While this process is increasingly well-characterized in breast cancer, a similar in-depth look at ECM stiffening remains lacking for prostate cancer. In this review, we scrutinize the current state of literature regarding ECM stiffening in prostate cancer and its potential association with disease progression and castration resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available